Clinical study
STEPS-CF / SASPject PT3.9
| Status | Not yet recruiting |
|---|---|
| Type | Trial |
| Countries | United Kingdom |
| Study years | 2027 (estimated)–2029 (estimated) |
| Entry review | 2026-10-03 |
Participation
Trial contacts: SASPiPhi Limited and Dr Freddy Frost, Liverpool Heart and Chest Hospital; listed trial center NIHR Liverpool Clinical Research Facility, Royal Liverpool University Hospital.
Check the study record or contact the study team for current recruitment and eligibility.
Study description
Phase1b/2a IV engineered phage antimicrobial for susceptible P. aeruginosa in adults18–60 with cystic fibrosis.
Study registrations
| ISRCTN | ISRCTN57413769 |
|---|
Related programs(1)
SASPiPhi Limited / STEPS-CF
Research/development
Recorded program–study link. Website
Notes from the source review
- Registry target64 differs from simplified cohort summary12+8+24. Preserve discrepancy; do not infer current enrollment from Ongoing.
Sources and updates
Entry reviewed . This is the date of our source review, not a confirmation of availability today.
AI helped us research this directory. Details may be wrong or out of date. Confirm availability with the clinic or study team. Suggest a correction.
| Study ID | isrctn57413769 |
|---|